Wavelight riding high on new Eye-Q approval

Article

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

The Eye-Q wavefront-guided LASIK procedure has been approved for the reduction or elimination of up to -7.00 D of spherical equivalent (SE) of myopia or myopia with astigmatism, with up to -7.00 D of spherical component and up to 3.00 D of astigmatic component at the spectacle plane.

The Eye-Q system has also been approved by the US regulatory body for the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.